Trastuzumab and chemotherapy are combined with another monoclonal antibody called pertuzumab (Perjeta) to treat HER2-positive breast cancer. It has demonstrated effectiveness in clinical studies and targets a distinct area of the HER2 receptor. The gene discussed is ERBB2; the disease is breast carcinoma.